Related Experiment Video
Updated: May 22, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death
Inge Verbrugge1, Ricky W Johnstone
1Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Abstract:
In this issue of Cancer Discovery, Bellail and colleagues unravel how overexpression of the ubiquitin-modifying enzyme A20 results in TNF-related apoptosis-inducing ligand (TRAIL) resistance in glioblastoma. After TRAIL receptor stimulation, A20 mediates the polyubiquitination of RIP1 at the TRAIL receptor tail, resulting in the interaction of the polyubiquin chain to procaspase-8 that is recruited to the TRAIL-bound receptors. The inability of ubiquitin-bound procaspase-8 to be dimerized and activated prevents the execution of the apoptotic program.
Insights
Overexpression of the A20 enzyme causes glioblastoma cells to resist TNF-related apoptosis-inducing ligand (TRAIL) therapy by blocking programmed cell death pathways. This resistance mechanism involves A20 preventing the activation of key proteins needed for apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Cell Death Mechanisms
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- TNF-related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent that induces cancer cell death.
- Resistance to TRAIL-mediated apoptosis is a major challenge in glioblastoma treatment.
Purpose of the Study:
- To investigate the role of the ubiquitin-modifying enzyme A20 in TRAIL resistance in glioblastoma.
- To elucidate the molecular mechanisms by which A20 confers resistance to TRAIL-induced apoptosis.
Main Methods:
- Analysis of A20 expression levels in glioblastoma.
- Investigating the interaction between A20, RIP1, and procaspase-8 following TRAIL receptor stimulation.
- Assessing the impact of A20 on RIP1 polyubiquitination and procaspase-8 activation.
Main Results:
- Overexpression of A20 was identified as a key factor in TRAIL resistance in glioblastoma.
- A20 mediates the polyubiquitination of RIP1 at the TRAIL receptor tail.
- This ubiquitination event prevents the dimerization and activation of procaspase-8, thereby inhibiting apoptosis.
Conclusions:
- A20 overexpression confers resistance to TRAIL-induced apoptosis in glioblastoma.
- Targeting A20 or its downstream signaling may represent a novel therapeutic strategy to overcome TRAIL resistance in glioblastoma.
